Project Grant R01AI194422
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $489,500 to The Children's Hospital of Philadelphia Research Institute on June 11, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This two-year project, which extends through May 31, 2027, focuses on developing novel sequencing methodologies and analytical pipelines to identify and characterize intact human immunodeficiency virus (HIV) reservoir cells...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Children's Hospital of Philadelphia Research Institute a $670,017 Project Grant effective February 4, 2026, through January 31, 2031, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This award funds basic biomedical research to define a novel regulatory pathway in type 2 lymphocytes that prevents chronic allergic lung inflammation and airways...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $489,500 Project Grant to The Children's Hospital Corporation (Boston Children's Hospital) on July 9, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project, titled "Overcoming Obstacles in Structural Elucidation of B Cell Antigen Receptor Assembly and Lateral Interaction," will be conducted through June 30, 2027, in Massachusetts. The research...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $853,112 to The Children's Hospital of Philadelphia Research Institute on February 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This Project Grant, with an ultimate completion date of January 31, 2031, funds research investigating the role of PILC1 and PILC2 pilus-associated proteins in Kingella kingae pathogenicity. Kingella kingae is an invasive...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $122,472 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Boston Children's Hospital on August 13, 2025, with a completion date of July 31, 2027. This award supports investigator-initiated research aimed at elucidating the molecular mechanisms underlying the activation and regulation of the NLRP3 inflammasome, a critical component of the...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital $151,040 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on December 4, 2025, to support a project extending through July 31, 2028. This Project Grant funds basic science research investigating the regulatory mechanisms of a small regulatory RNA (sRNA) designated BECO in Pseudomonas aeruginosa, a gram-negative bacterium that causes serious...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $3.15 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 1, 2025, with completion scheduled for August 31, 2029. The award supports investigator-initiated biomedical research examining the role of dendritic cell intrinsic unfolded protein response (UPR) pathways in driving...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $441,375 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 1, 2025, with a completion date of July 31, 2027. The award supports basic immunological research investigating the cell-specific roles of CD153 and CD30 in regulating immune responses, with particular focus on age-related immune...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a $267,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period April 16, 2026 through March 31, 2028. The award supports research into the molecular mechanisms of AIRE (Autoimmune Regulator), a transcription factor critical to immune tolerance. The research investigates how AIRE engages with peripheral tissue...
- Federal Project Grant Summary Boston Children's Hospital received a $905,875 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded May 19, 2026, with completion targeted for April 30, 2031. The grant funds research to elucidate the genetic mechanisms underlying B cell activation dysregulation in systemic lupus erythematosus (lupus), a leading cause of morbidity among youth in the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Children's Hospital of Philadelphia Research Institute a $906,255 Project Grant (CFDA 93.855: Allergy and Infectious Diseases Research) effective July 8, 2026, with completion targeted for June 30, 2031. This research project will deliver a comprehensive genetics-based discovery initiative to identify novel genes regulating Follicular Helper T Cell (TFH) function and their role in antibody responses. The research employs advanced variant-to-gene mapping methodologies including chromosome conformation analysis, quantitative expression-trait mapping, massively-parallel reporter assays, and CRISPR interference screening to identify disease-associated genetic variants and their functional impacts on TFH cells isolated from human lymphoid tissue. The award will produce validated research findings through parallel functional validation studies in in vitro lymphoid organoid models of human humoral immunity and in vivo mouse models of lupus and influenza vaccination. Deliverables include identification of novel effector genes regulating T cell-dependent antibody responses, mechanistic insights into how common genetic variation contributes to autoimmune disease susceptibility, and characterization of potential therapeutic intervention targets for modulating humoral immunity in vaccine development, infectious disease, and autoimmune disorder contexts. This work is conducted at the awardee's Philadelphia, Pennsylvania facility and will advance understanding of fundamental immunological mechanisms with direct applications to improving therapeutic interventions across multiple disease domains.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $906.3k | 7/8/26 |